MPM Oncology Impact Management as of Sept. 30, 2020
Portfolio Holdings for MPM Oncology Impact Management
MPM Oncology Impact Management holds 12 positions in its portfolio as reported in the September 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Repare Therapeutics Common (RPTX) | 17.7 | $74M | 2.4M | 30.77 | |
| TCR2 Therapeutics Common | 16.5 | $69M | 3.4M | 20.32 | |
| Harpoon Therapeutics Common | 16.0 | $66M | 3.9M | 16.99 | |
| iTeos Therapeutics Common (ITOS) | 14.0 | $58M | 2.4M | 24.67 | |
| Epizyme Common | 8.2 | $34M | 2.9M | 11.93 | |
| MEI Pharma Common | 7.6 | $32M | 10M | 3.12 | |
| Turning Point Therapeutics Common | 6.5 | $27M | 309k | 87.36 | |
| ADC Therapeutics Common (ADCT) | 4.3 | $18M | 540k | 32.99 | |
| G1 Therapeutics Common (GTHX) | 4.0 | $16M | 1.4M | 11.55 | |
| YmAbs Therapeutics Common (YMAB) | 3.1 | $13M | 337k | 38.39 | |
| Merus Common (MRUS) | 2.0 | $8.4M | 701k | 12.00 | |
| Autolus Therapeutics Common (AUTL) | 0.1 | $463k | 40k | 11.65 |
